870849-11-9Relevant academic research and scientific papers
Transition-metal-free C(sp3)-H/C(sp3)-H dehydrogenative coupling of saturated heterocycles with: N-benzyl imines
Deng, Guogang,Feng, Ping,Li, Minyan,Li, Tiantian,Liu, Zhengfen,Walsh, Patrick J.,Wei, Wanshi,Yang, Xiaodong,Zhang, Hongbin,Zi, Quanxing
, p. 7619 - 7625 (2020/10/05)
A unique C(sp3)-H/C(sp3)-H dehydrocoupling of N-benzylimines with saturated heterocycles is described. Using super electron donor (SED) 2-azaallyl anions and aryl iodides as electron acceptors, single-electron-transfer (SET) generates an aryl radical. Hydrogen atom transfer (HAT) from saturated heterocycles or toluenes to the aryl radical generates alkyl radicals or benzylic radicals, respectively. The newly formed alkyl radicals and benzylic radicals couple with the 2-azaallyl radicals with formation of new C-C bonds. Experimental evidence supports the key hydrogen-abstraction by the aryl radical, which determines the chemoselectivity of the radical-radical coupling reaction. It is noteworthy that this procedure avoids the use of traditional strong oxidants and transition metals. This journal is
Ring-Contraction Reaction of Substituted Tetrahydropyrans via Dehydrogenative Dual Functionalization by Nitrite-Catalyzed Double Activation of Bromine
Watanabe, Kazuhiro,Hamada, Tsukasa,Moriyama, Katsuhiko
, p. 5803 - 5807 (2018/09/21)
A nitrite-catalyzed ring contraction reaction of substituted tetrahydrofurans by oxidation of bromide under aerobic conditions as a dehydrogenative dual functionalization was developed to provide 2-acyltetrahydrofurans in good yields. On the other hand, the oxidation reaction of 1-substituted isochromans occurred via the bromohydroxylation to give 1-(dibromoalkyl)-1-hydroxyisochromans in high yields.
BICYCLIC HETEROCYCLE DERIVATIVES AND USE THEREOF AS GPR119 MODULATORS
-
Page/Page column 147-148, (2009/12/27)
The present invention relates to Bicyclic Heterocycle Derivatives of formula (I), compositions comprising a Bicyclic Heterocycle Derivative, and methods of using the Bicyclic Heterocycle Derivatives for treating or preventing obesity, diabetes, a metabolic disorder, a cardiovascular disease or a disorder related to the activity of GPR1 19 in a patient.
